Skip to main content

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

October 12, 2023

End Date

October 14, 2028
 

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

October 12, 2023

End Date

October 14, 2028